BioSpace News Archive

Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.

Like many other big pharma companies, Eli Lilly & Co. reported a good 2018 with a less optimistic view of 2019. Fourth-quarter 2018 revenue grew by 5 percent, driven by newer drugs. Operating expenses also went up by a percentage point. Full-year 2018 revenue grew by 7 percent to $24.556 billion.

Sickle cell disease is a genetic blood disorder that causes red blood cells to form abnormally, resulting in them taking on a shape like that of a sickle. This disease is incredibly debilitating and can be fatal. For thousands of years, many have suffered from sickle cell disease with little hope of it being cured.

First Light Diagnostics announced the addition of Dr. Peter Kaspar to the company’s board of directors effective January 1, 2019.

Syrris provides award-winning chemistry products to a range of research and development chemists and engineers, including Xeros Technology Group, a company specializing in novel and sustainable polymer solutions to advance the commercial laundry industry.

Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here’s the latest edition.

Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment

New Customers, More Products, and Expanding Capacity

During the president’s annual address to Congress and the nation, Trump said that as a result of his administration’s efforts to lower the costs of prescription drugs, “in 2018 drug prices experienced their single largest decline in 46 years.”

Shares of Rockville, Md.-based MacroGenics, Inc. have skyrocketed nearly 160 percent in premarket trading after the company announced its Phase III HER2-positive metastatic breast cancer study hit the mark.